The evolving landscape of biomarker testing for non-small cell lung cancer in Europe

Lung cancer remains the leading cause of cancer mortality worldwide [1]. Across Europe in 2018, there were an estimated 388,000 lung cancer-related deaths, which was higher than those related to colorectal cancer and breast cancer combined [2]. Non-small cell lung cancer (NSCLC) accounts for ∼84 % of all lung cancer cases [3], imposing a substantial social and financial burden in Europe [4,5].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research